- 期刊
- OpenAccess
Rifaximin Therapy of Irritable Bowel Syndrome
並列摘要
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder characterized by abdominal pain and altered bowel habits in the absence of specific organic pathology. Although the underlying pathogenesis of IBS is not well-understood, small intestinal bacterial overgrowth (SIBO) or other abnormalities in the gut flora is believed to contribute to the development of a subset of IBS cases. Rifaximin is a poorly absorbed antimicrobial with activity against enteric pathogens. A number of studies have shown a significant improvement in IBS symptoms with antibiotic therapy including rifaximin. In this review, we discuss the pharmacokinetics, in vitro susceptibility profile, and efficacy and safety data from clinical trials of rifaximin treatment of IBS.
延伸閱讀
- Romiti, R., Neto, M. L., & Nico, M. M. S. (2009). Response of Fibroblastic Rheumatism to Infliximab. Dermatology Research and Practice, 2009(), 60-61. https://doi.org/10.1155/2009/715729
- 蘇俊中（2014）。Medical Treatment of Crohn's Disease。臺灣臨床藥學雜誌，22(4)，251-257。https://doi.org/10.6168/FJCP.2014.2204.06
- 羅惠珍（2017）。TEDUGLUTIDE FOR THE TREATMENT OF SHORT BOWEL SYNDROME。秀傳醫學雜誌，16(2)，105-109。https://doi.org/10.3966/156104972017121602006
- Montfrans, C. V., Camoglio, L., & Deventer, S. J. H. V. (1998). Immunotherapy of Crohn's disease. Mediators of Inflammation, 1998(), 149-152. https://doi.org/10.1080/09629359891063
- 馮新偉（2009）。Quality of Life of 30 Cases of Patients with Irritable Bowel Syndrome。台灣中醫臨床醫學雜誌，15(4)，272-277。https://doi.org/10.6968/TJCCM.200912.0272